Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:03:45.378Z.
Calculation as of: 2026-10-06T16:03:45.378Z.
Quote observation: 2026-10-06T16:00:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$1.00B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$993.24M
EV/Sales Ratio
2.42x
TTM Avg
16.24x
3Y Avg
25.95x
5Y Avg
23.23x
Market Cap
$991.53M
EV/Sales Ratio
2.49x
TTM Avg
4.19x
3Y Avg
12.20x
5Y Avg
19.04x
Market Cap
$988.29M
EV/Sales Ratio
1.60x
TTM Avg
1.77x
3Y Avg
2.17x
5Y Avg
3.33x
Market Cap
$983.49M
EV/Sales Ratio
90.68x
TTM Avg
120.79x
3Y Avg
120.79x
5Y Avg
120.79x
Market Cap
$1.02B
EV/Sales Ratio
1.85x
TTM Avg
1.91x
3Y Avg
1.91x
5Y Avg
1.91x
Market Cap
$1.03B
EV/Sales Ratio
1.74x
TTM Avg
1.75x
3Y Avg
2.13x
5Y Avg
2.79x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $1.00B | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $993.24M | 2.42x | 16.24x | 25.95x | 23.23x |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.53M | 2.49x | 4.19x | 12.20x | 19.04x |
| Pacira BioSciences, Inc. (PCRX)vs › | $988.29M | 1.60x | 1.77x | 2.17x | 3.33x |
| Aktis Oncology, Inc. (AKTS)vs › | $983.49M | 90.68x | 120.79x | 120.79x | 120.79x |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.85x | 1.91x | 1.91x | 1.91x |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 1.74x | 1.75x | 2.13x | 2.79x |
| Immatics N.V. (IMTX)vs › | $1.04B | 16.33x | 15.40x | 10.40x | 9.15x |
| Kura Oncology, Inc. (KURA)vs › | $956.88M | 11.80x | 10.07x | 9.06x | 9.06x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
